Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAvacta Group Share News (AVCT)

Share Price Information for Avacta Group (AVCT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 40.25
Bid: 40.00
Ask: 40.50
Change: 0.25 (0.63%)
Spread: 0.50 (1.25%)
Open: 40.00
High: 40.50
Low: 39.75
Prev. Close: 40.00
AVCT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Avacta's Covid-19 test reaches prototype stage

Tue, 09th Jun 2020 09:30

(Sharecast News) - Avacta said its Covid-19 antigen test had reached prototype stage and could detect the virus in model samples.
The biotherapeutics company said a prototype assay of the test using its Affirmer reagents could detect the virus at concentrations in the range found in patient samples from standard throat swabs. The assay, developed with its US partner Adeptrix, had a "very high degree specificity".

The next step is to evaluate and optimise the assay using patient samples at laboratories in the US and UK. These will be carried out imminently before moving to manufacturing with clinical approval for professional use in the summer, Avacta said.

Alastair Smith, chief executive of Avacta, said: "I am very pleased with the rapid progress made by our partners at Adeptrix and delighted that the Affimer reagents that we have developed to detect the SARS-COV-2 spike protein are working very well in the BAMS assay.

"We are now looking forward to testing the prototype BAMS assay with patient samples in the UK very soon, whilst Adeptrix does the same at a site in the US. This will keep us on track for launch of a product for professional use in the summer."

Smith said Avacta was continuing to make very good progress on a saliva-based antigen test and that he would update the market soon on development of both products.

Avacta shares fell 9.4% to 129p at 10:14 BST. The shares have soared from 22p at the start of March as expectations have risen about the prospects for the company developing a Covid-19 test.

The AIM-traded company raised £48m on 4 June in a share placing to invest in faster development of Covid-19 tests and cancer therapies. The new shares are due to start trading on 10 June.





More News
14 Jul 2016 08:34

Avacta Collaborating With Glythera To Develop Antibody Drugs

Read more
22 Jun 2016 10:54

Avacta claims development could lead to early Zika diagnosis

(ShareCast News) - Avacta, biotherapeutics and research agent developer, reported on Wednesday it had identified three proteins which could be used to develop the first tests to diagnose early stages of the Zika virus. Avacta said it found three 'Affimer' proteins capable of binding to a form of sec

Read more
22 Jun 2016 06:37

Avacta Identifies Affimer Proteins For Possible Zika Virus Tests

Read more
13 Jun 2016 08:23

Avacta Forms Partnership With Mologic To Develop Point-Of-Care Tests

Read more
29 Apr 2016 14:37

DIRECTOR DEALINGS: Avacta Chief Operating Officer Buys Shares

Read more
25 Apr 2016 08:22

Avacta Making Good Progress On Programmes As Interim Loss Widens

Read more
19 Apr 2016 09:27

Avacta Group Hails Milestone In Multi-Affimer Production

Read more
18 Apr 2016 15:05

Earnings, Trading Statements Calendar - Week Ahead

Read more
7 Mar 2016 15:39

Avacta appoints scientific advisory board

(ShareCast News) - Avacta Group established what it saw as one of the last pieces in the management puzzle to get its products towards the market, appointing professors Terence Rabbitts, Paul Moss and Adrian Hayday to form the company's scientific advisory board on Monday. The AIM-traded developer o

Read more
24 Feb 2016 08:56

Avacta Gets Grant For Work To Help Reduce Use Of Animal Testing

Read more
25 Jan 2016 10:36

Avacta Poaches Abcam's Cotrel For Chief Commercial Officer Role

Read more
21 Jan 2016 10:24

Avacta Group Proposes 1-For-10 Share Consolidation (ALLISS)

Read more
10 Dec 2015 08:46

Avacta Appoints Tony Gardiner As Chief Financial Officer

Read more
26 Oct 2015 09:36

BROKER RATINGS SUMMARY: Investec Raises Senior To Buy From Hold

Read more
26 Oct 2015 09:35

Avacta Full-Year Loss Widens As It Ramps Up Affimer Investment

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.